fostemsavir
Author: Karolina Kujawa
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Fostemsavir (GSK3684934) (ViiV Healthcare), previously known as BMS-663068, is an oral prodrug of GSK2616713 (formerly BMS-626529). It is an attachment inhibitor which binds to the gp120 protein of HIV to prevent viral attachment to the host CD4+ T cells, which is necessary for entry into host cells. In December 2015, fostemsavir was acquired by ViiV Healthcare, which is now responsible for the development of the drug.
Fostemsavir is a novel oral attachment inhibitor being developed for use in multidrug-resistant patients, where there is significant unmet need for novel modes of action. Fostemsavir’s key differentiator over recently approved intravenous monoclonal antibody Trogarzo (ibalizumab; Theratechnologies/TaiMed Biologics) is its more convenient oral twice-daily dosing, which is expected to lower treatment costs for payers and patients. However, fostemsavir’s twice-daily dosing schedule is expected to preclude future progression to the earlier lines of therapy, where a plethora of more convenient once-daily regimens currently dominate.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 fostemsavir : HIV
LIST OF FIGURES
10 Figure 51: Datamonitor Healthcare’s drug assessment summary of cabotegravir/rilpivirine for HIV
11 Figure 52: Datamonitor Healthcare’s drug assessment summary of cabotegravir/rilpivirine for HIV
LIST OF TABLES
6 Table 1: Fostemsavir drug profile
8 Table 2: Late-phase trials of fostemsavir for HIV
9 Table 3: Fostemsavir for HIV – SWOT analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
cabotegravir/rilpivirine 
Sign up to the